Contact

Directors and Audit & Supervisory Board Members

Senior Executive Directors

  • Representative Director, Chairman

    Toru Ashida

    Profile
    April 1992
    Joined Nippon Life Insurance Company
    April 2002
    Appointed Representative Director and President at the establishment of JBS Co., Ltd.
    January 2014
    Joined the Company
    July 2014
    Appointed Corporate Officer of the Company
    Executive Director of Corporate Business Support Division and Director of Corporate Strategy Department of the Company
    April 2016
    Head of Office of the President of the Company
    June 2018
    Appointed Senior Executive Director of the Company
    Head of Quality Assurance Division, Corporate Planning Division, and Medical Affairs Department of the Company
    June 2019
    In charge of Corporate Strategy
    Head of Quality Assurance Division, Corporate Planning Division, Administration Division, and Medical Affairs Department of the Company
    April 2020
    Executive Director of Sales Division of the Company
    June 2020
    Appointed Vice President of the Company and in charge of Sales Division
    June 2021
    Appointed Senior Vice President of the Company and in charge of Sales and Administration
    April 2023
    In charge of Sales
    June 2024
    Appointed Director and Senior Managing Executive Officer of the Company
    April 2026
    Appointed Representative Director Chairman of the Company (to present)

  • Representative Director, President, Chief Scientific Officer

    Hiroyuki Sonoda, Ph.D.

    Profile
    April 2003
    Joined the Company
    April 2016
    Director of Corporate Planning Division (In charge of Research) of the Company
    October 2017
    Leader of Frontier Research Unit and Director of Corporate Planning Division (In charge of Research) of the Company
    April 2018
    Executive Director of Research Planning Division of the Company
    June 2018
    Appointed Corporate Officer of the Company
    June 2020
    Appointed Senior Executive Director of the Company and in charge of Research and Development Division
    Executive Director of Research Division, and Director of Drug Discovery Research Institute
    June 2021
    Appointed Vice President of the Company and in charge of Research and Corporate Strategy
    Executive Director of Research Division
    October 2022
    Representative Director and President of AlliedCel Corporation
    April 2023
    In charge of Research
    June 2024
    Appointed Director and Senior Managing Executive Officer of the Company
    April 2026
    Appointed Representative Director President of the Company (to present) Appointed Chief Scientific Officer of the Company (to present)

  • Director, Senior Managing Executive Officer, Development Division

    Andrea Spezzi, M.D., FFPM

    Profile
    June 1994
    Consultant Paediatrician / Staff Grade Paediatrician of
    Princess Alexandra Hospital, Saint Jamue Hospital, Pedro de Elizalde Children's Hospital
    March 2003
    Research Physician, Hammersmith Medicines Research
    November 2004
    Global Medical Director, Takeda Global R&D
    July 2009
    Vice President R&D, Medicines Development Leader Rare Diseases, Rare Diseases Business Unit of GlaxoSmithKline
    September 2015
    Founded Andrea Spezzi Executive Consultant (to present)
    January 2016
    Co-founder and Chief Medical Officer of Orchard Therapeutics
    June 2021
    Independent Board Director of Bloomsbury Genetic Therapies (to present)
    September 2021
    Co-Founder, President and CEO / Board Executive Director of Rejuvitas Inc.
    September 2023
    Advisor and acting Partner of Discovery Ventures Healthcare Fund (to present)
    December 2023
    Global Strategic Adviser of the Company
    June 2024
    Appointed Director and Managing Executive Officer of the Company In charge of Development (to present)
    April 2026
    Appointed Director and Senior Managing Executive Officer of the Company (to present)

  • Director, Managing Executive Officer, Executive Director, Quality Assurance Division

    Yoshio Hiyama, Ph.D.

    Profile
    April 1986
    Joined Daiichi Pharmaceuticals Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)
    October 1999
    PMD VAC Co., Ltd. (secondment)
    April 2005
    Manager of Regulatory Affairs Group of PMD VAC Co., Ltd.
    October 2011
    Daiichi Sankyo Co., Ltd. (returned), Group Manager of R&D Group of Vaccine Planning Dept.
    July 2012
    Japan Vaccines Co. Ltd. (secondment), Marketing Supervisor of General and Quality and Safety Management Director
    April 2019
    Joined the Company
    Assistant Director of Production Division
    April 2020
    Marketing Supervisor, General Director of Pharmacovigilance Dept., and PMS Office Manager
    September 2020
    Director of Corporate Planning Division (In charge of Vaccine Business) and Pharmacovigilance Dept.
    June 2021
    Appointed Senior Executive Director of the Company
    In charge of Production and Quality Assurance / Executive Director of Production Division
    March 2024
    Director of JCR Luxembourg S.A. (to present)
    April 2024
    In charge of Quality Assurance
    Executive Director of Quality Assurance Division and Director of Regulatory Affairs Department
    June 2024
    Appointed Director and Managing Executive Officer of the Company (to present)
    June 2024
    In charge of Quality Assurance
    Executive Director of Quality Assurance Division (to present)

  • Director, Founder

    Shin Ashida

    Profile
    September 1975
    Appointed Representative Director and President at the establishment of the Company
    June 2005
    Appointed Chairman of the Company
    Appointed Chief Executive Officer (CEO) of the Company
    June 2007
    Appointed President of the Company
    Appointed Chief Operating Officer (COO) of the Company
    April 2026
    Appointed Director and Founder of the Company (to present)

  • Outside Director (Independent)

    Takashi Suetsuna

    Profile
    April 1974
    Joined the National Police Agency
    February 1994
    Chief of Kochi Prefectural Police Headquarters
    September 1997
    Director of Finance Division of Commissioner-General's Secretariat of National Police Agency
    September 2001
    Chief Inspector General of Commissioner-General's Secretariat of National Police Agency
    August 2002
    Chief of Kanagawa Prefectural Police Headquarters
    August 2004
    Deputy Superintendent General of National Police Agency
    September 2005
    Grand Chamberlain to the Crown Prince at the Imperial Household Agency
    April 2009
    Ambassador Extraordinary and Plenipotentiary to Grand Duchy of Luxembourg
    June 2012
    Retired from the above office
    June 2013
    Outside Audit & Supervisory Board Member of Marubeni Corporation
    June 2015
    Outside Director of Totetsu Kogyo Co., Ltd.
    June 2016
    Outside Audit & Supervisory Board Member of Keikyu Corporation
    Outside Audit & Supervisory Board Member of Kandenko Co., Ltd. (to present)
    Appointed Outside Audit & Supervisory Board Member of the Company
    June 2017
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)
    June 2018
    Outside Audit & Supervisory Board Member of Aioi Nissay Dowa Insurance Co., Ltd.
    June 2025
    Outside Director (Audit and Supervisory Committee Member) of Keikyu Corporation (to present)

  • Outside Director (Independent)

    Yuko Hayashi, Ph.D.

    Profile
    April 1988
    Joined IBM Japan, Ltd.
    October 2003
    Visiting Researcher of Research Center for Advanced Science and Technology of The University of Tokyo
    April 2007
    Lecturer of Graduate School of Innovation and Technology Management of Yamaguchi University
    Visiting Researcher of National Graduate Institute for Policy Studies
    March 2011
    Executive Director of 3.11 Earthquake Orphans Cultural and Sports Support Facilitation Corporation of Public Interest Incorporated Association (to present)
    April 2012
    Associate Professor of Graduate School of Innovation and Technology Management of Yamaguchi University
    June 2015
    Professor of Graduate School of Innovation and Technology Management of Yamaguchi University (to present)
    January 2017
    Executive Board Member of Special Olympics Nippon Foundation
    April 2018
    Visiting Co-Researcher of Graduate School of Frontier Sciences of The University of Tokyo
    June 2018
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)

  • Outside Director (Independent)

    Yutaka Atomi, M.D., Ph.D.

    Profile
    April 1970
    Attending Surgeon of First Department of Surgery of Faculty of Medicine of The University of Tokyo
    April 1982
    Chief of Medical Staff of First Department of Surgery of Faculty of Medicine of The University of Tokyo
    June 1988
    Visiting Researcher of Department of Surgery of University of California, San Francisco
    July 1992
    Assistant Professor of First Department of Surgery of Faculty of Medicine of The University of Tokyo
    October 1992
    Professor of First Department of Surgery of Faculty of Medicine of Kyorin University
    April 2004
    Dean of Faculty of Medicine of Kyorin University
    April 2010
    President of Kyorin University
    June 2013
    Outside Audit & Supervisory Board Member of Sumitomo Dainippon Pharma Co., Ltd. (currently Sumitomo Pharma Co., Ltd.)
    June 2017
    Outside Director of Sumitomo Dainippon Pharma Co., Ltd. (currently Sumitomo Pharma Co., Ltd.)
    April 2018
    President Emeritus of Kyorin University (to present)
    June 2018
    President of Pancreas Research Foundation of Japan
    April 2019
    President of International Medical Research Foundation (to present)
    June 2019
    Outside Audit & Supervisory Board Member of Sanki Engineering Co., Ltd. (to present)
    June 2022
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)
    June 2023
    President of Atomi Gakuen (to present)
    Director of The Japan China Medical Association (to present)
    August 2023
    Outside Director of Pasona Inc.
    August 2025
    Outside Director (Audit and Supervisory Committee Member) of Pasona Inc. (to present)

  • Outside Director (Independent)

    Philippe Fauchet, OBE

    Profile
    October 1984
    Joined Roussel UCLAF S.A., France (currently, Aventis S.A.)
    September 1996
    Joined Sanofi S.A., France
    June 2001
    Appointed President and Representative Director of Sanofi-Synthelabo K.K. (currently, Sanofi K.K.)
    May 2005
    Appointed President and Representative Director of Sanofi-Aventis K.K. (currently, Sanofi K.K.)
    January 2010
    Appointed President and Representative Director of GlaxoSmithKline K.K.
    June 2013
    Appointed Outside Director of the Company
    April 2017
    Chairman of GlaxoSmithKline plc.
    November 2017
    Resigned as Outside Director of the Company
    February 2019
    Stepped down as Chairman of GlaxoSmithKline K.K.
    May 2019
    External Director of Bonac Corporation
    March 2020
    External Director of Noile-Immune Biotech Inc. (to present)
    September 2020
    External Director of Rezolute, Inc. (RZLT) (to present)
    June 2022
    Outside Director of LUCA Science Inc. (to present)
    June 2022
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)

  • Outside Director

    Marc Dunoyer

    Profile
    October 1999
    Representative Director Vice President of GlaxoWellcome K.K.
    March 2000
    Representative Director President of GlaxoWellcome K.K.
    January 2001
    Representative Director President of GlaxoSmithKline K.K.
    March 2003
    Corporate Executive Team Member of GlaxoSmithKline PLC
    May 2008
    Regional President of Asia Pacific & Japan of GlaxoSmithKline PLC
    January 2010
    Representative Director Chairman of GlaxoSmithKline K.K.
    February 2010
    Foundational Global Head of Rare Diseases Unit of GlaxoSmithKline PLC
    June 2010
    Outside Director of the Company
    April 2013
    Resigned as Outside Director of the Company
    June 2013
    Executive Vice President of Global Portfolio & Product Strategy of AstraZeneca PLC
    November 2013
    Member of the Board of Directors and Executive Director and Chief Financial Officer of AstraZeneca PLC
    Chairman of AstraZeneca K.K. (to present)
    June 2018
    Member of the Board of Directors of Orchard Therapeutics PLC
    August 2021
    Chief Executive Officer of Alexion, AstraZeneca's Rare Disease Group (to present)
    Chief Strategy Officer of AstraZeneca Group (to present)
    June 2023
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)
    December 2023
    Director of Cellectis SA (to present)

  • Outside Director

    Toshihide Yoda

    Profile
    April 1985
    Joined Nippon Kangyo Kakumaru Securities
    May 1989
    Joined UBS Securities Japan Co., Ltd.
    July 1996
    Joined ING Bearing Securities
    December 2000
    Joined Lehman Brothers Japan Inc.
    October 2008
    Joined Barclays Capital Securities Japan Limited (currently, Barclays Securities Japan Limited)
    Managing Director of Barclays Capital Securities Japan Limited (currently, Barclays Securities Japan Limited)
    June 2010
    Director of Medipal Holdings Corporation
    April 2012
    Managing Director of Medipal Holdings Corporation
    In charge of IR and General Manager of Business Development Department CMA®
    May 2016
    Director of SPLine Corporation
    Director of Medie Co., Ltd.
    June 2016
    Director of Mediceo Corporation
    February 2018
    Director of JCR USA, Inc. (to present)
    June 2018
    Senior Vice President of Medipal Holdings Corporation (to present)
    Appointed Member of the Board of Directors (Outside Director) of the Company (to present)
    June 2022
    General Manager of Business Development Department of Medipal Holdings Corporation (to present)

Outside Audit & Supervisory Board Member

  • Independent Audit & Supervisory Board Member

    Kazumasa Oizumi

    Profile
    March 1992
    Manager of Utsunomiya Branch of Nippon Life Insurance Company
    March 1997
    President of Nihonbashi Branch of Nippon Life Insurance Company
    March 2001
    Manager of Fourth Department of Metropolitan Area Agency of Nippon Life Insurance Company
    June 2002
    Standing Audit & Supervisory Board Member of SOHGO SECURITY SERVICES CO., LTD.
    April 2009
    Executive Officer of SOHGO SECURITY SERVICES CO., LTD.
    June 2013
    Appointed Outside Audit & Supervisory Board Member of the Company (to present)
    June 2014
    Full-Time Audit & Supervisory Board Member of the Company (to present)

  • Independent Audit & Supervisory Board Member

    Masayuki Mitsuka

    Profile
    April 1982
    Joined Mitsubishi Chemical Industries (currently Mitsubishi Chemical Corporation)
    June 2009
    Board Director, Executive Officer, and General Manager of Global Product Strategy Department of Mitsubishi Tanabe Pharma Corporation(currently Tanabe Pharma Corporation)
    April 2012
    Board Director, Managing Executive Officer, and Division Manager of Development Division of Mitsubishi Tanabe Pharma Corporation
    April 2014
    Representative Director and Senior Managing Executive Officer of Mitsubishi Tanabe Pharma Corporation
    June 2014
    President & Representative Director and Chief Executive Officer of Mitsubishi Tanabe Pharma Corporation
    April 2020
    Board Director of Mitsubishi Tanabe Pharma Corporation
    June 2020
    Advisor of Mitsubishi Tanabe Pharma Corporation
    July 2022
    Advisor of Medipal Holdings Corporation
    June 2023
    External Director of SAWAI GROUP HOLDINGS Co., Ltd. (to present)

  • Independent Audit & Supervisory Board Member

    Miya Miyama

    Profile
    October 2002
    Appointed Public Prosecutor (Public Prosecutor, Tokyo District Public Prosecutors Office)
    July 2013
    Head of Compliance Department of The Innovation Network Corporation of Japan
    July 2016
    Retired from position as Public Prosecutor
    Registered as an attorney at law of Japan Federation of Bar Associations (member of Dai-Ichi Tokyo Bar Association) Attorney of CITY-YUWA PARTNERS (to present)
    April 2018
    Permanent Member of Dai-Ichi Tokyo Bar Association
    April 2020
    Vice Chair of Gender Equality Committee of Kanto Federation of Bar Associations
    June 2021
    Outside Director of Totetsu Kogyo Co., Ltd. (to present)
    March 2022
    Directors and Audit & Supervisory Board Members
    June 2025
    Outside Corporate Auditor of GS Yuasa Corporation (to present)

Corporate Officers

  • Senior Managing Executive Officer, Executive Director, Administration Division, Head of Executive Office

    Yutaka Honda

  • Senior Managing Executive Officer, Executive Director, Business Development Division

    Toshihiro Ishikiriyama

  • Managing Executive Officer, Executive Director, Corporate Strategy Division

    Yoh Ito

  • Managing Executive Officer, Executive Director, Production Division

    Makoto Ashida

  • Managing Executive Officer, Executive Director, Development Division, JCR Europe B.V. General Manager, JCR USA Inc. CEO

    Anne Bechet

  • Senior Executive Officer, Director, International Affairs Office

    Takayo Egawa

  • Executive Officer, Executive Director, Sales Division

    Tomohiko Miyagawa

  • Executive Officer, Executive Director, Research Division and Director, CMC Research Institute

    Kazutoshi Mihara

  • Executive Officer, Director, Legal and Compliance Department, Internal Control Department Chief Legal and Compliance Officer

    Hiroyuki Fukuya